Article Figures & Data
Tables
- Table 1
MICs and error rates obtained for 107 single-patient clinical isolates of the Acinetobacter baumannii-calcoaceticus complex tested for susceptibility to imipenem, meropenem, and doripenem by manual and automated methods compared to BMD by using CLSI, FDA, and EUCAST criteria
Drug and methoda MIC (μg/ml) Resultb using the following criteria: CLSIc FDAd EUCASTe 50% 90% % S % VME % ME % mE % S % VME % ME % mE % S % VME % ME % mE Imipenem DD 39.6 0.0 0.9 1.9 39.6 0.0 0.9 1.9 31.8 0.0 0.0 19.6 ET ≥32 ≥32 39.3 0.0 0.9 3.7 39.3 0.0 0.9 3.7 13.1 0.0 0.0 12.1 MicroScan ≥8 ≥8 43.0 3.7 1.9 2.8 43.0 3.7 1.9 2.8 38.3 0.9 0.9 53.3 Phoenix ≥8 ≥8 41.1 1.9 0.9 2.8 41.1 1.9 0.9 2.8 37.4 0.9 0.0 23.4 Vitek 2 ≥16 ≥16 39.3 0.9 0.0 4.7 39.3 0.9 0.0 4.7 38.3 0.0 0.0 27.1 BMD ≥16 ≥16 37.4 37.4 15.0 Meropenem DD 38.3 0.0 0.0 3.7 38.3 0.0 0.0 3.7 8.4 0.0 0.0 14.0 ET ≥32 ≥32 36.4 0.0 0.0 3.7 36.4 0.0 0.0 3.7 19.6 0.0 0.0 12.0 MicroScan ≥8 ≥8 38.3 0.0 0.9 3.7 38.3 0.0 0.9 3.7 37.4 0.0 0.9 21.3 Phoenix ≥8 ≥8 39.2 1.9 0.9 4.7 39.2 1.9 0.9 4.7 35.5 1.9 0.9 15.9 Vitek 2 ≥16 ≥16 39.3 0.0 0.9 4.7 39.3 0.0 0.9 4.7 36.4 0.0 0.0 18.7 BMD ≥16 ≥16 35.5 35.5 19.6 Doripenem DD NA NA NA NA 35.5 30.8 0.9 NA 7.5 0.0 0.0 11.2 ET ≥32 ≥32 NA NA NA NA 6.5 2.8 0.0 NA 6.5 0.0 0.0 8.4 Vitek 2 ≥8 ≥8 NA NA NA NA 21.5 17.8 0.0 NA 21.5 1.9 0.0 20.6 BMD ≥16 ≥16 NA 3.7 3.7 ↵a DD, disk diffusion; ET, Etest; Vitek 2, Vitek 2 cards (AST-GN24 card and AST-XN04 extension card).
↵b S, susceptible; VME, very major errors; ME, major errors; mE, minor errors; NA, not applicable (intermediate breakpoints for doripenem were not defined).
↵c CLSI breakpoints for imipenem/meropenem were as follows: for susceptibility, ≤4 μg/ml (≥16 mm); for intermediacy, 8 μg/ml (14 to 15 mm); for resistance, ≥16 μg/ml (≤13 mm) (3).
↵d FDA breakpoints were as follows: for imipenem/meropenem, ≤4 μg/ml (≥16 mm) for susceptibility, 8 μg/ml (14 to 15 mm) for intermediacy, and ≥16 μg/ml (≤13 mm) for resistance; for susceptibility to doripenem, ≤1 μg/ml (≥17 mm).
↵e EUCAST breakpoints were as follows: for imipenem, ≤2 μg/ml (≥23 mm) for susceptibility and >8 μg/ml (<17 mm) for resistance; for meropenem, ≤2 μg/ml (≥21 mm) for susceptibility and >8 μg/ml (<15 mm) for resistance; for doripenem, ≤1 μg/ml (≥21 mm) for susceptibility and >4 μg/ml (<15 mm) for resistance (6). Values between susceptible and resistant are considered intermediate.
